Age-Related Macular Degeneration
Ching-Yu Cheng, Tien Yin Wong in Ophthalmic Epidemiology, 2022
As a disorder affecting probably first the retinal pigment epithelium (RPE), AMD is characterized in its early and medium advanced stage by structural and pigmentary irregularities of the RPE, including the formation of drusen as deposits beneath the RPE and above Bruch’s membrane.61 In addition, a detachment of the RPE may develop and subretinal drusenoid deposits may form. In the late stage of AMD, the RPE can get lost in the case of geographic atrophy and/or a fibrovascular scar with proliferation of the RPE can develop as a sequel of a choroidal neovascularization in the foveal region. These changes result in a central relative or absolute scotoma while the peripheral visual field is usually not affected. Since landmark clinical trials demonstrated in 2006 the therapeutic benefit of intravitreally applied antibodies against vascular endothelial growth factor (VEGF), repeated intravitreal injections of ranibizumab, bevacizumab, aflibercept, and conbercept significantly improved vision in treated patients compared to untreated patients in control groups.62–64 Correspondingly, recent population-based data have suggested that legal AMD-related blindness has been reduced by 50% in some countries since the introduction of VEGF antagonists.65,66
One-Year Outcome of Conbercept Therapy for Diabetic Macular Edema
Published in Current Eye Research, 2018
Fengjiao Li, Le Zhang, Yanling Wang, Wenwen Xu, Wanzhen Jiao, Aihua Ma, Bojun Zhao
Conbercept (KH902; Chengdu Kanghong Biotech Co., Ltd., Sichuan, China), a novel reagent of anti-VEGF, is a full humanized, soluble, VEGF receptor (VEGFR) protein. Its molecular weight is 143 kDa. It contains extracellular domain-2 of VEGFR-1, and extracellular domains-3 and-4 of VEGFR-2.The structure is similar to aflibercept but they differ in that conbercept contains a fourth VEGFR-2 binding domain, which enhances the association rate of VEGF and prolongs its half-life in the vitreous. Compared to ranibizumab and bevacizumab, the most notable characteristic of conbercept is that it binds not only VEGF-A, but also VEGF-B, and placental growth factor (PIGF)—all with high affinity. Furthermore, the preclinical studies have also shown that conbercept has advantages over ranibizumab and bevacizumab in that it has a longer half-life and a stronger binding affinity to VEGF-A.10Conbercept has been approved to treat neovascular age macular disease by the China Food and Drug Administration in December 2013. The efficacies of conbercept in the treatment of polyploidchoroid vasculopathy have been reported.11 We also have reported that the conbercept is effective in the treatment of macular edema secondary to branch retinal vein occlusion.12 However, there is few report about the efficacy of conbercept for the treatment of diabetic macular edema. The aim of this retrospective study was to investigate the clinical efficacy of conbercept for treatment diabetic macular edema with different baseline BCVA levels.
Updates on the Management of Ocular Vasculopathies with VEGF Inhibitor Conbercept
Published in Current Eye Research, 2020
Huan Liu, Yue Ma, Hong-Chang Xu, Li-Ying Huang, Li-Ying Zhai, Xiao-Rong Zhang
In the past decade, dramatic changes in the management of PDR and retinal vascular disease have been seen through the introduction of VEGF inhibitors. The first available anti-VEGF drug, pegaptanib, is a 28-nucleotide long aptamer, which binds to the VEGF-A 165 isomer.71 Preoperative intravitreal VEGF inhibitors have been widely applied currently. It has been proved that anti-VEGF treatment before vitrectomy decreases many complications and surgical procedures, including intraoperative bleeding, iatrogenic retinal breaks, early postoperative bleeding, the use of endo-diathermy, and duration of surgery.71–74 Currently three available VEGF antagonists, bevacizumab, ranibizumab, and aflibercept, have been developed and investigated in patients with PDR.71 Conbercept is a member of the anti-VEGF drugs. It was developed to provide a prolonged and more potent anti-VEGF effect.
Retinal vein occlusion: drug targets and therapeutic implications
Published in Expert Opinion on Therapeutic Targets, 2021
Alessandro Arrigo, Francesco Bandello
The rationale for the use of conbercept has already been demonstrated in several retinal diseases, including RVO. The molecular characteristics of this novel anti-VEGF drug make it possible to target various isoforms of VEGF-A, VEGF-B and PGF [48]. Conbercept is currently under investigation in two independent clinical trials involving neovascular age-related macular degeneration patients, namely PANDA-1 (NCT03577899] and PANDA-2 (NCT03630952]. Positive results regarding the efficacy and safety of conbercept have also been found in the treatment of diabetic macular edema [77]. The administration of conbercept also led to significant morpho-functional improvements in RVO, displaying a good safety profile and efficacy comparable with that of other treatments [78–81], together with statistically significant reductions of pro-inflammatory cytokines and mediators [82].
Related Knowledge Centers
- Choroidal Neovascularization
- Diabetic Retinopathy
- Intraocular Pressure
- Macular Degeneration
- Vascular Endothelial Growth Factor
- Neovascularization
- Anti-Vegf
- Phases of Clinical Research
- Near-Sightedness
- Intravitreal Injection